News

CetuGEX showed improved anti-tumor activities, reduced side effects and a broader patient and indication range. The 1:1 randomized Phase IIb trial is designed to assess the efficacy and

Under the deal, Evotec will be responsible for discovery and pre-clinical development efforts, while Debiopharm will manage clinical development. The deal will see Evotec receive R&D funding and

The patent issued today expires in 2023. Eagle’s dantrolene formulation for the treatment of Exertional Heat Stroke (EHS) was granted Orphan Drug designation by the Food and Drug

TD2 chief development officer Daniel Von Hoff said the Nuvilex team presents them with a new tool to employ against the symptoms and invasive properties of this very

Under the agreement, Particle Sciences is responsible for design, formulation and cGMP supplies. Actavis will have responsibility for clinical testing, regulatory filings and marketing. Particle Sciences CEO Mark

This model is used for drug stratification and identification of personalized drug treatments for cancer patients. The work began through a joint project between Alacris and the SAP(R)

Currently, Azedra is in Phase II registrational trial in patients suffering from pheochromocytoma and paraganglioma. Progenics CEO Mark Baker said CPDC, and their host, McMaster University, serve as

SMA is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. It is caused by a genetic defect in the SMN1 gene, which codes

Once-daily PREZISTA is indicated for the treatment of HIV-1 in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations. PREZISTA is always taken with and at the